Phase I study of combination treatment with PTK 787/ZK 222584 (PTK/ZK) and cetuximab for patients with advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and toxicity analysis

被引：0
|
作者：
Langenberg, M. H. [1 ,2 ,3 ]
Witteveen, P. O. [1 ,2 ,3 ]
Lankheet, N. [1 ,2 ,3 ]
Roodhart, J. M. [1 ,2 ,3 ]
Rosing, H. [1 ,2 ,3 ]
Beijnen, J. H. [1 ,2 ,3 ]
Voest, E. E. [1 ,2 ,3 ]
机构：
[1] Univ Med Ctr Utrecht, Utrecht, Netherlands
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Slotervaart Hosp, Amsterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2575
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase 1-2 Trial of PTK787/ZK222584 Combined With Intravenous Doxorubicin for Treatment of Patients With Advanced Hepatocellular Carcinoma
    Yau, Thomas
    Chan, Pierre
    Pang, Roberta
    Ng, Kelvin
    Fan, S. T.
    Poon, Ronnie T.
    CANCER, 2010, 116 (21) : 5022 - 5029
  • [32] Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK): Evaluating the pharmacokinetic effect of a high-fat meal in patients with hormone-refractory prostate cancer (HRPC).
    George, D
    Oh, W
    Gilligan, T
    Masson, E
    Souppart, C
    Wang, Y
    Ho, Y
    Lebwohl, D
    Laurent, D
    Kantoff, P
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 428S - 428S
  • [33] Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
    Drevs, J
    Zirrgiebel, U
    Schmidt-Gersbach, CIM
    Mross, K
    Medinger, M
    Lee, L
    Pinheiro, J
    Wood, J
    Thomas, AL
    Unger, C
    Henry, A
    Steward, WP
    Laurent, D
    Lebwohl, D
    Dugan, M
    Marmé, D
    ANNALS OF ONCOLOGY, 2005, 16 (04) : 558 - 565
  • [34] A Phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients
    Pavel, M.
    Schuppan, D.
    Jost, L.
    Kerr, D.
    Harris, A.
    Jalava, T.
    Masson, E.
    Palacay-Radona, M. L. D.
    Koehne, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 427 - 427
  • [35] Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate
    Joensuu, H.
    De Braud, F.
    Coco, P.
    De Pas, T.
    Putzu, C.
    Spreafico, C.
    Bono, P.
    Bosselli, S.
    Jalava, T.
    Laurent, D.
    Casali, P. G.
    ANNALS OF ONCOLOGY, 2008, 19 (01) : 173 - 177
  • [36] Biomarkers for the assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Comparison of preclinical data with results in phase I studies.
    Lee, L
    McSheehy, P
    Morgan, B
    Laird, G
    Allegrini, P
    Cozens, R
    Dugan, M
    Laurent, D
    Lebwohl, D
    Sharma, S
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6203S - 6203S
  • [37] EORTC Study 26041-22041: Phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with or without PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma-Results of a phase I trial
    Brandes, A. A.
    Stupp, R.
    Hau, P.
    Sleijfer, S.
    Lacombe, D.
    Gorlia, T.
    Yun, H.
    Tosoni, A.
    Mirimanoff, R.
    van den Bent, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers
    Juretzka, M. M.
    Aghajanian, C.
    Hensley, M. L.
    Tew, W. P.
    Spriggs, D.
    Konner, J.
    Chiang, A. C.
    Pezzulli, S.
    Kim, M.
    Sabbatini, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation
    Zips, D
    Krause, M
    Hessel, F
    Westphal, J
    Brüchner, K
    Eicheler, W
    Dörfler, A
    Grenman, R
    Petersen, C
    Haberey, M
    Baumann, M
    ANTICANCER RESEARCH, 2003, 23 (5A) : 3869 - 3876
  • [40] MRI-assessed changes in tumor blood flow after treatment with PTK787/ZK222584 (PTK/ZK) correlate with subsequent tumor shrinkage or growth in patients with metastatic renal cell carcinoma
    de Bazelaire, C
    Alsop, D
    Rofsky, N
    Wang, YY
    Mietlowski, W
    Reitsma, D
    Laurent, D
    Michaelson, D
    Kantoff, P
    George, D
    Oh, WK
    ANNALS OF ONCOLOGY, 2005, 16 : 17 - 17
12345